Cerimon currently is conducting a Phase II study (ARREST UC-1) of Simulect® (basiliximab) in patients with moderate-to-severe ulcerative colitis (Study BSX-001: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis).

To learn more about the details of this study and to find out if the study is enrolling patients in your area, please call 1.650.827.4035 or go to www.arrestuc.com/sites.html.